{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:23Z","timestamp":1790744483101,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Atopic dermatitis (AD), bullous pemphigoid (BP), and alopecia areata (AA) are immune-mediated dermatologic diseases characterized by distinct clinical features but partially overlapping immunopathogenic mechanisms. Their coexistence in a single patient is uncommon and may pose significant diagnostic and therapeutic challenges. We report the case of a 33-year-old woman with long-standing moderate-to-severe AD who subsequently developed BP, confirmed by histopathology and direct immunofluorescence. Initial treatment with systemic corticosteroids and conventional immunosuppressants, including azathioprine followed by cyclosporine, resulted in only transient improvement and was limited by adverse effects. Dupilumab was therefore initiated, leading to marked improvement of BP while maintaining remission of AD. However, after approximately six months of therapy, the patient developed new-onset patchy AA. Dupilumab was discontinued, and treatment was switched to upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor. Early clinical improvement was observed after six weeks, with progressive hair regrowth and stable BP activity. Complete remission of BP was achieved after twelve weeks and complete remission of AA after twenty-four weeks, while remission of AD was maintained. Disease control was sustained throughout a twenty-four -month follow-up, without significant adverse events. This case underscores the diagnostic and therapeutic complexity associated with the coexistence of multiple immune-mediated dermatologic diseases. The sequential emergence of AD, BP, and AA highlights the challenges posed by overlapping inflammatory pathways and the need for alternative therapeutic strategies when pathway-specific treatments prove insufficient or poorly tolerated. These observations support the concept that broader immunomodulatory approaches targeting shared signaling pathways may enable simultaneous control of multiple inflammatory conditions. In this context, inhibition of the JAK\u2013STAT pathway may represent a promising integrated therapeutic strategy in selected patients with complex immune-mediated dermatologic comorbidities.<\/jats:p>","DOI":"10.3389\/fmed.2026.1959635","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:46:17Z","timestamp":1790743577000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Sara","family":"Triolo","sequence":"first","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredo","family":"Bruni","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Maria","family":"Magnanimi","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Berardinis","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mozzato","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Mastrangelo","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila","place":["L'Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The Translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1128154","DOI":"10.3389\/fmed.2023.1128154","article-title":"The cytokine milieu of bullous pemphigoid: current and novel therapeutic targets","volume":"10","author":"Maglie","year":"2023","journal-title":"Front Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2024270","DOI":"10.5826\/dpc.1404a270","article-title":"Dupilumab and alopecia areata: a possible combined or disturbance therapy? A review of the literature","volume":"14","author":"Starace","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/cea.13729","article-title":"Bidirectional association between alopecia areata and atopic dermatitis: a population-based cohort study in Taiwan","volume":"50","author":"Wei","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00403-022-02372-w","article-title":"Association between bullous pemphigoid and atopic dermatitis: a population-based case-control study in Taiwan","volume":"315","author":"Wu","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","article-title":"European guideline (EuroGuiDerm) on atopic eczema: living update","volume":"39","author":"Wollenberg","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","volume-title":"A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA). Identifier: NCT06012240","year":"2026"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s00403-025-04203-0","article-title":"Atopic dermatitis and bullous pemphigoid: shared pathogenic mechanisms and potential pathways linking the two conditions","volume":"317","author":"Fan","year":"2025","journal-title":"Arch Dermatol Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s13555-025-01536-6","article-title":"Dermatologic comorbidities associated with atopic dermatitis towards a shared therapeutical approach: a narrative review","volume":"15","author":"Esposito","year":"2025","journal-title":"Dermatol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13023","DOI":"10.1111\/dth.13023","article-title":"Dupilumab and alopecia: a Janus effect","volume":"32","author":"Patruno","year":"2019","journal-title":"Dermatol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2050313X231160926","DOI":"10.1177\/2050313X231160926","article-title":"A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report","volume":"11","author":"Gresham","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"E85","DOI":"10.1097\/DER.0000000000000780","article-title":"Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata","volume":"32","author":"Gambardella","year":"2021","journal-title":"Dermatitis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2200873","DOI":"10.1080\/09546634.2023.2200873","article-title":"Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report","volume":"34","author":"Pan","year":"2023","journal-title":"J Dermatol Treat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/jdv.19377","article-title":"Upadacitinib in concurrent Crohn's Disease, atopic dermatitis and alopecia areata: a case report","volume":"38","author":"Novielli","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e15346","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.abd.2023.07.003","article-title":"Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata","volume":"99","author":"Muzy","year":"2024","journal-title":"An Bras Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/CCID.S467026","article-title":"Treatment of refractory segmental vitiligo and alopecia areata in a child with upadacitinib and NB-UVB: a case report","volume":"17","author":"Mu","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2302394","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100323","DOI":"10.1016\/j.jacig.2024.100323","article-title":"Successful treatment of the dupilumab-induced psoriatic dermatitis\/arthritis and atopic dermatitis with a JAK inhibitor: a case report and literature review","volume":"3","author":"Tsunoda","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/imj.16484","article-title":"Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib","volume":"54","author":"Yiu","year":"2024","journal-title":"Intern Med J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100269","DOI":"10.1016\/j.jacig.2024.100269","article-title":"Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient","volume":"3","author":"Giavina-Bianchi","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2528704","DOI":"10.1080\/09546634.2025.2528704","article-title":"Management of comorbid Crohn's Disease and alopecia universalis with upadacitinib and oral minoxidil","volume":"36","author":"Levine","year":"2025","journal-title":"J Dermatol Treat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jdcr.2025.06.033","article-title":"A case of psoriasis and atopic dermatitis-like rash induced by interleukin-17 and interleukin-23 inhibitors successfully controlled with upadacitinib","volume":"63","author":"Okazaki","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000544703","article-title":"Upadacitinib monotherapy in vitiligo associated with atopic dermatitis: killing two birds with one stone","volume":"17","author":"Magnanimi","year":"2025","journal-title":"Case Rep Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1795986","DOI":"10.3389\/fimmu.2026.1795986","article-title":"Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1959635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:46:28Z","timestamp":1790743588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1959635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1959635"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1959635","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1959635"}}